Skip to main content
|

Add a bookmark to get started

Bookmarks info
ting xiao large

Ting Xiao

Partner
Regional Life Sciences Lead, Asia
Shanghai
About

Ting is a Partner in the IPT practice of DLA Piper's Shanghai office. She is Regional Life Sciences Lead for Asia and also co-leads the firm’s Life Sciences practice in China. Her practice focuses on patents, trade secrets and other technology-related matters. She specializes in licensing and technology transfer, life sciences and healthcare related regulatory work, and also handles IP enforcement and litigation matters.

Prior to her legal career, Ting worked as a research scientist in the National Key Laboratory of Chinese Academy of Sciences and a renowned research institute in Canada. Ting leverages her advanced scientific research background and deep understanding of client’s technical field to routinely advise clients from a wide variety of emerging and innovative sectors, including life sciences and healthcare, chemical, automotive, information technology, artificial intelligence and new energy.

Areas of FocusLife SciencesIntellectual PropertyTechnology
Professional QualificationsAttorney-at-law admitted with the Supreme Court of New YorkBarrister and Solicitor registered with The Law Society of Upper Canada

EXPERIENCE

  • Representing one of the largest Chinese pharmaceutical CDMOs/CROs in multiple cross-border transactions, including an in-license of DNA library screening technology from a top U.S. university, a joint development and collaboration agreement with a U.S. supplier of API compounds, and multiple outbound service agreements.
  • Advising a large Vietnamese conglomerate on a complex technology and IP in-licensing, component supply and services transaction with a Chinese state-owned automobile manufacturer involving the Chinese automobile OEM’s electrical and electronic (E/E) architecture.
  • Representing an Irish company in a distribution arrangement with one of the largest pharmaceutical conglomerate in China relating to a novel drug.
  • Acting for a major U.S. lithium battery company in negotiating and drafting a joint development and manufacturing agreement with a Central State Owned Enterprise for the manufacture of ultrahigh capacitor batteries in China for use in the public transport road and rail infrastructure.
  • Advising a major Chinese OEM of electronic devices in a legal action brought by its licensor in U.S. concerning disputes on royalty payment and trademark infringement.
  • Advising a U.S. application-delivery-networking-technology company on complex transaction with Chinese partner to have networking equipment “made in China” and distributed in China, including preparing manufacturing and IP license agreement as well as component supply agreement.
  • Advising a German banking IT system provider on complex licensing, back licensing and technology transfer issues in connection with its joint venture arrangement with a Chinese state-owned enterprise.
  • Advising a major American manufacturer of diagnostic healthcare products on various NMPA regulatory and compliance issues concerning its China entry.
  • Advising a leading Chinese high-tech company on the U.S. Export Administration Regulations (EAR) and sanctions.
Languages
  • Chinese (Mandarin)
  • English
Education
  • University of Toronto, Juris Doctor
  • University of Toronto, Master of Science
  • Wuhan University, Bachelor of Science (Ranked 2nd out of 210)

Awards

  • Ting has been recognized as “Up-and-Coming” for Intellectual Property practice by Chambers Greater China Region 2024.
  • Ting has been recognized as “Up-and-Coming” for Life Sciences practice by Chambers Greater China Region 2024.
  • Ting has been recognized as “Patent Star” by Managing Intellectual Property 2023-2024.
  • Ting has been recognized as "Next Generation Partner” for China Life Sciences and Healthcare practice by Legal 500 Asia Pacific 2023-2024.

Publications

2018 Outlook for Drugs and Medical Devices in China: Regulatory Reform Fueled by Innovation

My latest insights

Past event

What does your board need to know about the pharmaceutical landscape in China?

13 November 2024 .2 minute read

News

IP Stars recognizes 33 from DLA Piper's global IP practice in annual rankings

18 June 2024 .3 minute read

News
Abstract architecture

DLA Piper advises Calliditas Therapeutics in connection with Asahi Kasei’s US$1.1 billion...

4 June 2024 .2 minute read

View All

Connect

Phone

+86 21 3852 2111
(Work, Shanghai)
CallvCardLinkedInPrint
Privacy policyYour privacy choicesLegal noticesCookie policyFraud AlertMake a paymentSitemap

DLA Piper is a global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA Piper's structure, please refer to the Legal Notices page of this website. All rights reserved. Attorney advertising.

© 2024 DLA Piper US